Chargement en cours...
A CRITICAL ASSESSMENT OF EDARAVONE ACUTE ISCHEMIC STROKE EFFICACY TRIALS: IS EDARAVONE AN EFFECTIVE NEUROPROTECTIVE THERAPY?
IMPORTANCE OF THE FIELD: Edaravone (Radicut®) is a free radical scavenger marketed in Japan by Mitsubishi Tanabe Pharma Corporation to treat acute ischemic stroke (AIS) patients presenting within 24 hours of the attack. Injectable edaravone ampoules (30mg b.i.d, i.v., 14 days) were first approved on...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891515/ https://ncbi.nlm.nih.gov/pubmed/20491547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2010.493558 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|